Search

Displaying results 5361 - 5370 of 9333 in total
  1. Drug

    Astegolimab

    go.drugbank.com/drugs/DB16386
    Investigational

    Astegolimab is under investigation in clinical trial NCT04386616 (A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia).

  2. Drug

    Indoprofen

    go.drugbank.com/drugs/DB08951
    ApprovedWithdrawn

    Following reports of adverse reactions including reports of carcinogenicity in animal studies it was withdrawn from the market worldwide.

  3. Drug

    Tetrathiomolybdate

    go.drugbank.com/drugs/DB05088
    Investigational

    It is also developed for fibrotic disorders based upon the rationale that the fibrotic disease process is dependent upon the availability of free copper in the body. … COPREXA has completed pivotal clinical trials for the treatment of neurologic Wilson's disease.

  4. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.

  5. Drug

    Nevadistinel

    go.drugbank.com/drugs/DB21632
    Investigational

    The usage of the INN stem '-stinel' in the name indicates that Nevadistinel is a N-methyl-D-aspartate (NMDA) receptor co-agonist. … Nevadistinel is under investigation in clinical trial NCT04148391 (NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory

  6. Drug

    NB-001

    go.drugbank.com/drugs/DB12716
    Investigational

    NB-001 has been investigated for the treatment of Recurrent Herpes Labialis.

  7. Drug

    SJG-136

    go.drugbank.com/drugs/DB11965
    Investigational

    SJG-136 has been used in trials studying the treatment of Recurrent Fallopian Tube Cancer, Secondary Acute Myeloid Leukemia, de Novo Myelodysplastic Syndromes, Recurrent Ovarian Epithelial Cancer, and

  8. Drug

    beta-Naphthoflavone

    go.drugbank.com/drugs/DB06732
    Experimental

    It may be a chemopreventive agent. … β-Naphthoflavone, also known as 5,6-benzoflavone, is a potent agonist of the aryl hydrocarbon receptor and induces cytochromes P450 (CYPs) and uridine 5'-diphospho-glucuronosyltransferases (UGTs).

  9. Drug

    Vibriolysin

    go.drugbank.com/drugs/DB05135
    Experimental

    Vibriolysin is a proteolytic enzyme secreted by the marine microorganism Vibrio proteolyticus. … It is a new agent for enzymatic debridement, shown to rapidly and thoroughly hydrolyze burn wound eschar within full-thickness wounds.

  10. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    This follows an earlier decision to discontinue development of eplivanserin for schizophrenia. … In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant.